Atea Pharmaceuticals Files 8-K on Financials
Ticker: AVIR · Form: 8-K · Filed: May 12, 2025 · CIK: 1593899
| Field | Detail |
|---|---|
| Company | Atea Pharmaceuticals, Inc. (AVIR) |
| Form Type | 8-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Atea Pharma filed an 8-K for financial updates, no major news yet.
AI Summary
Atea Pharmaceuticals, Inc. filed an 8-K on May 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these categories.
Why It Matters
This filing indicates that Atea Pharmaceuticals is providing updates on its financial condition and results of operations to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial reporting and does not disclose any new material events or risks.
Key Players & Entities
- Atea Pharmaceuticals, Inc. (company) — Registrant
- May 12, 2025 (date) — Report Date
- 225 Franklin Street Suite 2100 Boston, MA 02110 (address) — Principal Executive Offices
FAQ
What specific financial results or conditions are being reported by Atea Pharmaceuticals in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific results or conditions within the provided text.
When was this 8-K report filed by Atea Pharmaceuticals?
The report was filed on May 12, 2025.
What is the primary purpose of this 8-K filing for Atea Pharmaceuticals?
The primary purpose is to report on the company's results of operations and financial condition, and to include financial statements and exhibits.
Does the filing mention any changes to Atea Pharmaceuticals' former name or address?
The filing states 'N/A' for 'Former Name or Former Address, if Changed Since Last Report', indicating no such changes are being reported.
What is Atea Pharmaceuticals' principal executive office address?
Atea Pharmaceuticals' principal executive office is located at 225 Franklin Street, Suite 2100, Boston, MA 02110.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding Atea Pharmaceuticals, Inc. (AVIR).